A MORE TRADITIONAL TYPE VAX IN THE WORKS:
Saint Herblain (France), October 18, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive topline results from the Phase 3 pivotal trial Cov-Compare of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
Valneva’s Chief Executive Officer, Thomas Lingelbach, and the trial’s Chief Investigator, Adam Finn, Professor of Paediatrics at the University of Bristol, will comment on the results in a live webcast beginning at 3 p.m. CET today. Please refer to this link: https://edge.media-server.com/mmc/p/3zmb7nnp.
ThankQ !!
BookmarQed!!
“A MORE TRADITIONAL TYPE VAX IN THE WORKS:”
At this point I will never allow the medical industry to put a needle in me ever again.
They can’t be trusted to put what they say is in the needle in the needle and nothing else.